Cancer-associated heterozygous mutations in IDH1 and IDH2 result in the formation of wild-type-mutant heterodimers with neomorphic activity, allowing the reduction of α-KG to 2-hydroxyglutarate (2HG) in the presence of NADPH [82,83,84,85]. The gene discussed is IDH2; the disease is cancer.